Calciphylaxis Clinical Trial
Official title:
Better Evidence and Translation for Calciphylaxis
This global platform study will evaluate multiple interventions, across several domains of therapeutic care, in adult patients with kidney failure and newly diagnosed calciphylaxis.
BEAT-Calci is a randomized, adaptive, multi-center, platform trial that will evaluate multiple interventions, across several domains of therapeutic care. The objective of the study is to establish high-quality evidence on the effect of a range of interventions in patients with kidney failure and newly diagnosed calciphylaxis. Calciphylaxis is a rare disease affecting 1-2 people in 10,000. The trial will commence with a Dialysis Membrane Domain and Pharmacotherapy Domain. The Pharmacotherapy Domain of BEAT-Calci is a placebo-controlled, double blind, response adaptive, randomised controlled trial that will investigate whether any of the pharmacotherapeutic agents is superior to placebo in improving outcomes. The Dialysis Membrane Domain of BEAT-Calci is an open-label, randomised controlled two-way comparison between two different dialysis technologies. The BEAT-Calci Wound Assessment Scale (BCWAS) is the primary endpoint for the trial. It is an 8-point ordinal categorical scale of disease outcomes and will be used to determine each participant's outcome. The trial will utilise a Bayesian adaptive sample size re-estimation approach for sample size calculations. The trial will continue to recruit until predefined superiority or futility rules are met. As the trial progresses, in response to information accumulating during the trial, there are various adaptations that can occur, including addition or removal of an intervention arm, response adaptive randomisation and addition of new therapeutic domains. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT01578382 -
Pathophysiology of Martorell Hypertensive Ischemic Leg Ulcer (HYTILU)
|
||
| Active, not recruiting |
NCT04592640 -
Stem Cells for Uremic Calciphylaxis Patients
|
N/A | |
| Terminated |
NCT03319914 -
Observational Follow-up to ST-001 Calciphylaxis Pain Treatment With Intravenous Sodium Thiosulfate
|
||
| Recruiting |
NCT06065852 -
National Registry of Rare Kidney Diseases
|
||
| Terminated |
NCT03150420 -
A Phase 3 Clinical Trial of Intravenous Sodium Thiosulfate in Acute Calciphylaxis Patients
|
Phase 3 | |
| Completed |
NCT02790073 -
Phase 2 Study With SNF472 in Calciphylaxis Patients
|
Phase 2 | |
| Recruiting |
NCT03146793 -
The Early Administration of Sodium Thiosulfate Should Help to Reduce the Mortality of Dialysis Patients With Calciphylaxis, From a National Cohort
|
N/A | |
| Completed |
NCT02278692 -
Evaluation of Vitamin K Supplementation for Calcific Uremic Arteriolopathy
|
N/A | |
| Completed |
NCT02854046 -
Calciphylaxis : Population, Risk Factors, Diagnostic Practice, Therapeutic and Outcome
|
||
| Terminated |
NCT02527213 -
Randomized Double Blind Placebo Controlled Trial of Sodium Thiosulfate for the Treatment of Pain Associated With Calcific Uremic Arteriolopath
|
Phase 3 | |
| Recruiting |
NCT03032835 -
Partners Calciphylaxis Biobank
|
||
| Completed |
NCT01289626 -
Efficacy of Lanthanum Carbonate in Calciphylaxis
|
Phase 1 | |
| Recruiting |
NCT06283589 -
The SEAPORT 1 Study: Evaluation of the Safety and Tolerability of INZ-701 in Adults With End-Stage Kidney Disease Undergoing Hemodialysis
|
Phase 1 | |
| Completed |
NCT04195906 -
Phase 3 Study of SNF472 for Calciphylaxis
|
Phase 3 | |
| Recruiting |
NCT02635373 -
European Calciphylaxis Registry Network
|
N/A |